DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

N/A

Manufactured by Thea Pharma Inc.

14,333 FDA adverse event reports analyzed

Last updated: 2026-04-14

About DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Thea Pharma Inc.. The most commonly reported adverse reactions for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE include EYE IRRITATION, OCULAR HYPERAEMIA, DRUG INEFFECTIVE, EYE PAIN, EYE PRURITUS. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE.

Top Adverse Reactions

EYE IRRITATION779 reports
OCULAR HYPERAEMIA639 reports
DRUG INEFFECTIVE584 reports
EYE PAIN474 reports
EYE PRURITUS390 reports
INTRAOCULAR PRESSURE INCREASED364 reports
DEATH335 reports
VISION BLURRED327 reports
GLAUCOMA275 reports
FATIGUE272 reports
DYSPNOEA263 reports
EYE SWELLING247 reports
OFF LABEL USE235 reports
HEADACHE223 reports
HYPERSENSITIVITY215 reports
DIZZINESS214 reports
FALL211 reports
LACRIMATION INCREASED207 reports
NAUSEA206 reports
ASTHENIA199 reports
DIARRHOEA197 reports
PAIN187 reports
VISUAL IMPAIRMENT170 reports
VOMITING168 reports
PNEUMONIA165 reports
HYPERTENSION160 reports
DRUG HYPERSENSITIVITY158 reports
VISUAL ACUITY REDUCED155 reports
CATARACT153 reports
TREATMENT FAILURE153 reports
GAIT DISTURBANCE148 reports
ARTHRALGIA144 reports
PRODUCT QUALITY ISSUE143 reports
CONDITION AGGRAVATED141 reports
RASH141 reports
BRONCHITIS122 reports
DRY EYE120 reports
COUGH115 reports
PRURITUS114 reports
WEIGHT DECREASED114 reports
DRUG INTOLERANCE112 reports
SYNCOPE109 reports
CONFUSIONAL STATE103 reports
DRUG DOSE OMISSION103 reports
EYE DISCHARGE102 reports
BLOOD PRESSURE INCREASED101 reports
MALAISE101 reports
URINARY TRACT INFECTION99 reports
ERYTHEMA97 reports
BRADYCARDIA94 reports
DIVERTICULITIS92 reports
NO ADVERSE EVENT90 reports
ANAEMIA89 reports
HYPOTENSION88 reports
MUSCULAR WEAKNESS88 reports
ACUTE KIDNEY INJURY87 reports
RHEUMATOID ARTHRITIS87 reports
INSOMNIA86 reports
DECREASED APPETITE84 reports
PAIN IN EXTREMITY83 reports
SCIATICA83 reports
ALOPECIA82 reports
ANXIETY82 reports
LOSS OF CONSCIOUSNESS82 reports
COLITIS MICROSCOPIC79 reports
DRUG INTERACTION79 reports
SYNOVITIS79 reports
CONSTIPATION78 reports
PYREXIA78 reports
ATRIAL FIBRILLATION77 reports
BACK PAIN76 reports
DYSGEUSIA76 reports
BLINDNESS75 reports
EYE DISORDER75 reports
MYOCARDIAL INFARCTION75 reports
PRODUCT DOSE OMISSION ISSUE75 reports
FOREIGN BODY SENSATION IN EYES74 reports
ABDOMINAL PAIN73 reports
CHEST PAIN73 reports
OEDEMA PERIPHERAL73 reports
INJECTION SITE REACTION71 reports
SOMNOLENCE71 reports
HAND DEFORMITY70 reports
PARAESTHESIA69 reports
DEPRESSION66 reports
PHOTOPHOBIA66 reports
HYPONATRAEMIA65 reports
C REACTIVE PROTEIN INCREASED64 reports
CONTRAINDICATED PRODUCT ADMINISTERED64 reports
CEREBROVASCULAR ACCIDENT62 reports
EYE INFLAMMATION62 reports
HEPATIC ENZYME INCREASED61 reports
DEHYDRATION60 reports
EYELID OEDEMA60 reports
HYPOAESTHESIA60 reports
MOBILITY DECREASED60 reports
MYALGIA60 reports
FEELING ABNORMAL59 reports
THYROID DISORDER59 reports
BLINDNESS UNILATERAL58 reports

Report Outcomes

Out of 7,716 classified reports for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE:

Serious 55.2%Non-Serious 44.8%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female4,349 (59.4%)
Male2,931 (40.0%)
Unknown42 (0.6%)

Reports by Age

Age 74159 reports
Age 75155 reports
Age 73154 reports
Age 83151 reports
Age 72134 reports
Age 71131 reports
Age 80130 reports
Age 69128 reports
Age 76127 reports
Age 78123 reports
Age 79123 reports
Age 84122 reports
Age 82121 reports
Age 81120 reports
Age 70116 reports
Age 77116 reports
Age 67114 reports
Age 85114 reports
Age 87105 reports
Age 64102 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE?

This profile reflects 14,333 FDA FAERS reports that mention DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE?

Frequently reported terms in FAERS include EYE IRRITATION, OCULAR HYPERAEMIA, DRUG INEFFECTIVE, EYE PAIN, EYE PRURITUS, INTRAOCULAR PRESSURE INCREASED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE?

Labeling and FAERS entries often list Thea Pharma Inc. in connection with DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.